BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21 2023 - 6:01AM
Business Wire
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company, today announced that the Company will
participate in the 42nd Annual J.P. Morgan Healthcare Conference on
Monday, January 8th, 2024 with a presentation at 1:30 pm PT.
A live webcast of this event can be accessed from the investors
section of BeiGene’s website at http://ir.beigene.com,
https://hkexir.beigene.com/, https://sseir.beigene.com/. Archived
replays will be available for 30 days following the event.
About BeiGene
BeiGene is a global biotechnology company that is discovering
and developing innovative oncology treatments that are more
accessible and affordable to cancer patients worldwide. With a
broad portfolio, we are expediting development of our diverse
pipeline of novel therapeutics through our internal capabilities
and collaborations. We are committed to radically improving access
to medicines for far more patients who need them. Our growing
global team of more than 10,000 colleagues spans five continents,
with administrative offices in Basel; Beijing; and Cambridge, U.S.
To learn more about BeiGene, please visit www.beigene.com and
follow us on LinkedIn and X (formerly known as Twitter) at
@BeiGeneGlobal.
Forward-Looking Statements
This presentation may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene's plans, commitments, aspirations and goals related to
BeiGene’s medicines and drug candidates. Actual results may differ
materially from those indicated in the forward-looking statements
as a result of various important factors which are discussed in the
section entitled “Risk Factors” in BeiGene’s most recent quarterly
report on Form 10-Q filed with the U.S. Securities and Exchange
Commission (“SEC”) as well as discussions of potential risks,
uncertainties, and other important factors in BeiGene's subsequent
filings with the SEC. All information in this presentation is as of
the date presented, and BeiGene undertakes no duty to update such
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231221718490/en/
Investors: Liza Heapes +1 857-302-5663 ir@beigene.com
Media: Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2024 to May 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From May 2023 to May 2024